Shareholders of Denmark-based Medical Prognosis Institute A/S voted in favor of the company's merger with Oncology Venture Sweden AB.
Under the deal, Oncology Venture stockholders will exchange each share they hold for 1.8524 Medical Prognosis Institute shares. They will own about 51.3% of the merged entity.
Medical Prognosis Institute is a precision medicine company that develops drugs to treat cancer using its drug response predictor technology. Oncology Venture Sweden develops anticancer drugs.
